{"filings":[{"id":178371,"accession_number":"0001213900-25-004220","cik":1811115,"company_name":"Renalytix plc","ticker":"RNLXY","form_type":"8-K","filed_at":"2025-01-16T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Renalytix reverts to foreign private issuer SEC filing status effective Jan 1, 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Company determined it qualifies as FPI as of Dec 31, 2024; will cease domestic issuer filings.","Effective Jan 1, 2025, Renalytix will file periodic reports using FPI forms.","Company had previously been an FPI but filed as domestic since July 1, 2023.","Change may reduce SEC reporting burden (e.g., no quarterly 10-Q, different GAAP allowed)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":7866336.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195027,"accession_number":"0001213900-24-111219","cik":1811115,"company_name":"Renalytix plc","ticker":"RNLXY","form_type":"8-K","filed_at":"2024-12-20T23:59:59+00:00","items":["5.07","7.01","9.01"],"status":"ready","headline":"Renalytix announces all 9 resolutions passed at 2024 AGM","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All resolutions passed with strong support; Resolution 1 (adopt accounts) received 99.86% votes for.","Resolution 2 (directors' remuneration report) passed with 86.76% for, 13.24% against.","Resolution 6 (share issuance under 2020 EIP) passed with 83.99% for, 16.01% against.","Resolution 9 (share buyback authorization) passed with 99.83% for, 0.17% against.","Approximately 65% of ordinary shares were represented at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":7866336.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195024,"accession_number":"0001213900-24-100211","cik":1811115,"company_name":"Renalytix plc","ticker":"RNLXY","form_type":"8-K/A","filed_at":"2024-11-19T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Renalytix raises £11.6M in private placement and restructures $11.7M convertible bonds","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of £2.16M from first tranche (24M shares) and £9.43M from second tranche (104.7M shares) at £0.09 per share.","Insiders acquired 14.86M shares; all insider shares subject to six-month lock-in.","£2.97M of bonds converted to 33M shares; remaining balance restructured as 5.5%/7.5% convertible loan note due July 2029, conversion at 250% of Issue Price.","$850k advisor accounts payable restructured: $425k converted to shares at Issue Price; $325k to unsecured note at 5% due in 5 years or change of control.","Net proceeds used for sales/marketing, general corporate expenses, and ~10% for EHR integrations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":7866336.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195026,"accession_number":"0001213900-24-095002","cik":1811115,"company_name":"Renalytix plc","ticker":"RNLXY","form_type":"8-K","filed_at":"2024-11-06T23:59:59+00:00","items":["5.02","5.07","7.01","9.01"],"status":"ready","headline":"Renalytix director Levangie resigns; shareholders authorize share allotment up to ~35% of enlarged capital","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dan Levangie resigned as Non-Executive Director effective Oct 31, 2024, citing no disagreement.","Shareholders passed all three resolutions with >98.7% votes in favor at Oct 31 general meeting.","Board authorized share allotment up to ~35% of enlarged share capital; specific nominal amounts for bonds/placements.","Julian Baines MBE appointed as director effective from close of GM with 99.85% votes in favor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":7866336.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195025,"accession_number":"0001193125-24-230319","cik":1811115,"company_name":"Renalytix plc","ticker":"RNLXY","form_type":"8-K","filed_at":"2024-10-01T23:59:59+00:00","items":["1.01","2.01","2.02","2.03","3.01","3.02","8.01","9.01"],"status":"ready","headline":"Renalytix launches £10M placing, restructures debt, plans Nasdaq delisting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Minimum £10M gross raised at 9p/share; first tranche of £2.1M closes Oct 9, second tranche conditional on shareholder vote.","FY24 preliminary IFRS revenue $2.3M, loss before tax $44.9M (incl. $10.2M impairment), cash $4.7M, net liabilities -$8.5M.","Convertible bond restructured: £2.75M of $11.66M principal converted to shares; balance to new 5.5%/7.5% note due 2029.","Voluntary delisting from Nasdaq effective ~Oct 7; ADSs to trade on OTCQX Marketplace."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":7866336.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211314,"accession_number":"0000950170-24-100790","cik":1811115,"company_name":"Renalytix plc","ticker":"RNLXY","form_type":"8-K","filed_at":"2024-08-27T23:59:59+00:00","items":["3.01","7.01","9.01"],"status":"ready","headline":"Renalytix gets Nasdaq extension to Oct 25, 2024; transfers to Capital Market","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq Hearings Panel grants until October 25, 2024 to regain compliance with minimum bid price of $1.00.","ADSs transfer from Nasdaq Global Market to Nasdaq Capital Market effective August 27, 2024.","Must also achieve $2.5M minimum stockholders' equity and provide 12-month income projections.","Unaudited cash position $4.7M as of June 30, 2024; cash runway into Q4 2024.","Advanced discussions with stakeholders for funding and refreshed business plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":7866336.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211313,"accession_number":"0000950170-24-083385","cik":1811115,"company_name":"Renalytix plc","ticker":"RNLXY","form_type":"8-K","filed_at":"2024-07-15T23:59:59+00:00","items":["3.02","7.01","9.01"],"status":"ready","headline":"Renalytix repays $1.06M of convertible bond with shares and ADSs","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued 2.275M ordinary shares and 4.641M ADSs to settle $1.06M principal and interest due July 7, 2024.","Remaining convertible bond principal reduced to $11.66M from $12.72M.","Shares issued under Section 3(a)(9) exemption; no registration.","11.56M new ordinary shares to be admitted to AIM on July 17, 2024.","Post-Admission total ordinary shares: 165,925,513; each ADS represents two ordinary shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":7866336.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229894,"accession_number":"0000950170-24-077428","cik":1811115,"company_name":"Renalytix plc","ticker":"RNLXY","form_type":"8-K/A","filed_at":"2024-06-25T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Renalytix replaces auditor; EY out, CohnReznick in for FY2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Audit committee dismissed EY effective June 18, 2024; engaged CohnReznick LLP as new auditor for FY ending June 30, 2024.","EY's reports for FY2023, 2022, 2021 had no adverse opinion, except a going-concern explanatory paragraph for FY2023.","No disagreements with EY on accounting principles; past material weakness in stock-based compensation internal control was remediated by June 30, 2023.","Auditor change part of cost-reduction and optimization of third-party support services."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":7866336.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229906,"accession_number":"0000950170-24-076884","cik":1811115,"company_name":"Renalytix plc","ticker":"RNLXY","form_type":"8-K","filed_at":"2024-06-24T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Renalytix receives Nasdaq delisting notice; intends to appeal by June 28","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq determined company did not regain compliance with minimum bid price ($1.00) and MVLS ($50M) by June 19, 2024.","Unless appeal is filed by June 28, ADS trading will be suspended at opening on July 2, 2024, and Form 25-NSE filed.","Company intends to request a hearing before Nasdaq Hearings Panel, which will stay suspension pending decision.","Plan to present a strategic plan to regain compliance; no assurance of acceptance or success.","Delisting could impair liquidity, accurate quotations, and ability to raise capital."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":1.0,"calibrated_materiality_score":1.0,"market_cap_usd":7866336.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229905,"accession_number":"0000950170-24-076873","cik":1811115,"company_name":"Renalytix plc","ticker":"RNLXY","form_type":"8-K","filed_at":"2024-06-24T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Renalytix appoints CohnReznick as auditor, dismisses EY after cost review","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Audit committee selected CohnReznick as new independent registered public accounting firm for FY ending June 30, 2024, effective June 19, 2024.","Ernst & Young dismissed effective June 18, 2024; EY reports for FY 2021-2023 contained no adverse opinion except a going concern explanatory paragraph in 2023.","No disagreements with EY on accounting principles or practices; prior material weakness in stock-based compensation remediated as of June 30, 2023.","Auditor change part of cost reduction and optimization of third-party support services."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":7866336.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229904,"accession_number":"0000950170-24-074280","cik":1811115,"company_name":"Renalytix plc","ticker":"RNLXY","form_type":"8-K","filed_at":"2024-06-17T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Medicare finalizes coverage for Renalytix's kidneyIntelX.dkd at $950/test effective Aug 1, 2024","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Medicare issued final Local Coverage Determination (LCD) for kidneyIntelX.dkd; effective dates of service on/after August 1, 2024.","Established Medicare price is $950 per test; distinct CPT codes published in CMS 2024 Clinical Lab Fee Schedule.","Coverage applies to patients with Type 2 diabetes and Stage 1-3b Chronic Kidney Disease per FDA label.","LCD issued by National Government Services (NGS), a Medicare Administrative Contractor for the company's NYC lab.","CEO expects coverage to prompt additional major insurance decisions and accelerate test adoption."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":7866336.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229903,"accession_number":"0000950170-24-072531","cik":1811115,"company_name":"Renalytix plc","ticker":"RNLXY","form_type":"8-K","filed_at":"2024-06-12T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Appoints Joel Jung as Interim CFO with $8k/month salary and 60k options","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Interim CFO Joel Jung receives $8,000 monthly base salary under consulting agreement.","Option grant of 60,000 ordinary shares; 1/4 vest Aug 28, 2024, rest monthly over 9 months.","Exercise price equals closing price of ordinary shares on AIM on day before grant.","Options fully vest upon change in control; agreement terminable with 3 months' notice."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":7866336.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229902,"accession_number":"0000950170-24-064882","cik":1811115,"company_name":"Renalytix plc","ticker":"RNLXY","form_type":"8-K","filed_at":"2024-05-28T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"CFO O. James Sterling resigns effective May 24; Joel R. Jung appointed interim CFO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO O. James Sterling resigned May 24, 2024; will remain through transition period ending June 10, 2024.","Board appointed Joel R. Jung as interim CFO effective May 28, 2024; Jung was previously CFO at Minerva Surgical (2020-2024).","CEO stated company is focused on cost reductions and commercial adoption of KidneyIntelX with FDA approval and reimbursement.","Resignation did not involve any disagreement with the company; Jung has no material interest in related-party transactions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":7866336.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229901,"accession_number":"0000950170-24-060084","cik":1811115,"company_name":"Renalytix plc","ticker":"RNLXY","form_type":"8-K","filed_at":"2024-05-15T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Renalytix enters $15M at-the-market equity offering with H.C. Wainwright","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company may sell ADSs with aggregate offering price up to $15M on Nasdaq through H.C. Wainwright.","Placement fee of 3% of gross sales; company reimburses certain agent expenses.","Agreement effective May 15, 2024; no obligation to sell any ADSs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":7866336.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229900,"accession_number":"0000950170-24-060026","cik":1811115,"company_name":"Renalytix plc","ticker":"RNLXY","form_type":"8-K","filed_at":"2024-05-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Renalytix Q3 revenue $0.5M; net loss $7.7M; strategic sale process initiated","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $0.5M, down from $0.7M YoY; net loss narrowed to $7.7M from $12.1M.","Cash and equivalents $4.7M; operating cash burn $4.9M, down ~40% from prior quarter.","Total test volume 806 (82% billable); primary care orders up 33% QoQ.","Strategic sale process initiated with multiple potential acquirers in discussions.","FDA-authorized kidneyintelX.dkd launched April 2024; Medicare coverage draft issued."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.27,"consensus_revenue_estimate":null,"consensus_revenue_actual":1703000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":7866336.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229899,"accession_number":"0000950170-24-048658","cik":1811115,"company_name":"Renalytix plc","ticker":"RNLXY","form_type":"8-K","filed_at":"2024-04-26T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Renalytix closes second tranche of private placement, raises ~$7M gross","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Second Tranche of 26,815,841 ordinary shares at £0.20 each closed on April 24, 2024, following shareholder approval.","Gross proceeds from Second Tranche ~$7M; net proceeds expected to extend cash runway into calendar Q4 2024.","Post-issuance total ordinary shares outstanding: 154,368,191.","Company to file resale registration statement with SEC within 45 days of Second Closing.","First Tranche of 19,986,031 shares closed March 14, 2024; combined offering proceeds extend runway."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":7866336.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229898,"accession_number":"0000950170-24-047020","cik":1811115,"company_name":"Renalytix plc","ticker":"RNLXY","form_type":"8-K","filed_at":"2024-04-23T23:59:59+00:00","items":["1.01","5.02","5.07","9.01"],"status":"ready","headline":"Renalytix president McLain resigns, Howard Doran appointed; equity offering expanded","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Thomas McLain resigns as President effective April 30, 2024; severance includes 6 months base salary ($450K) and accelerated vesting of 12 months of options.","Howard Doran appointed President effective April 30, 2024; base salary increased to $350K from $300K.","Investor DB Capital exercised option to buy 1,333,334 additional shares at $0.375/share, raising net ~$0.5M.","Shareholders approved allotment of up to 26.8M new ordinary shares and related pre-emptive waivers with >98% support.","Original option exercise period extended to April 22, 2024 via letter agreement; total offering includes 4M shares at $0.375."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":7866336.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229897,"accession_number":"0000950170-24-043336","cik":1811115,"company_name":"Renalytix plc","ticker":"RNLXY","form_type":"8-K","filed_at":"2024-04-10T23:59:59+00:00","items":["3.02","7.01","9.01"],"status":"ready","headline":"Renalytix repays $1.06M of convertible bonds with ADSs; outstanding principal now $12.72M","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued 1,818,081 ADSs (3,636,162 ordinary shares) on April 11, 2024 to settle $1.06M of principal and interest due April 7, 2024.","Principal remaining on 5.5% convertible bonds due April 2027 reduced by $1.06M to $12.72M.","New ordinary shares admitted to AIM on April 12, 2024; total voting rights rise to 123,552,349.","Shares issued without SEC registration under Section 3(a)(9) exemption.","Repayment covers quarterly installment for period from January 8, 2024 to April 7, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":7866336.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229896,"accession_number":"0000950170-24-043030","cik":1811115,"company_name":"Renalytix plc","ticker":"RNLXY","form_type":"8-K","filed_at":"2024-04-09T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Renalytix raises $1M in registered direct offering at $0.375/share, with option for up to $3.9M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 2,666,667 ordinary shares at $0.375 each for gross proceeds of approximately $1.0 million.","Investor has option until April 17, 2024 to purchase up to 7,811,696 additional shares at same price, potentially raising $3.9M total.","Initial closing expected April 11, 2024; subsequent tranche closing by April 19, 2024 if option exercised.","Offering made under effective shelf registration statement on Form S-3 (File No. 333-274733)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":7866336.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229895,"accession_number":"0000950170-24-042424","cik":1811115,"company_name":"Renalytix plc","ticker":"RNLXY","form_type":"8-K","filed_at":"2024-04-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Renalytix raises up to $4M in registered direct offering with DB Capital Partners","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Initial tranche of $1.0M at $0.75 per ADS ($0.375 per ordinary share) closing by April 11.","Optional second tranche of up to ~$3M at same price, exercisable until April 17.","Net proceeds to support commercial sales activity and ongoing Formal Sale Process.","Purchaser DB Capital Partners Healthcare will hold ~2.18% of shares after initial closing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":7866336.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248372,"accession_number":"0000950170-24-038614","cik":1811115,"company_name":"Renalytix plc","ticker":"RNLXY","form_type":"8-K","filed_at":"2024-03-29T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Renalytix amends bond agreement with CVI, adds beneficial ownership cap and payment deferral rights","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Amendment with CVI Investments adds a 9.99% beneficial ownership limitation on bondholder's ordinary shares.","Removes daily cap on ADS sales; shortens market price observation periods to 5 and 3 days.","Majority bondholders (>50% principal) can defer the April 7, 2024 scheduled amortization payment.","Majority bondholders also gain right to accelerate deferred April 2024 payment and future scheduled payments."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":7866336.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248371,"accession_number":"0000950170-24-031141","cik":1811115,"company_name":"Renalytix plc","ticker":"RNLXY","form_type":"8-K","filed_at":"2024-03-14T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"KidneyIntelX included in final KDIGO 2024 guideline for CKD risk prediction","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["KidneyIntelX recommended for predicting CKD progression in stages G1-G3 per KDIGO 2024 guideline released March 13.","FDA de-novo marketing authorization for kidneyintelX.dkd received June 2023 for use in type 2 diabetes patients.","Outcomes data from >2,500 patients showed sustained reduction in eGFR decline and improved diabetes/cardiovascular management.","Current enrollment >9,000 patients with type 2 diabetes and CKD for ongoing clinical utility and outcomes studies.","Guideline emphasizes risk prediction and personalized treatment; Renalytix aims to expand evidence base."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":7866336.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248370,"accession_number":"0000950170-24-030496","cik":1811115,"company_name":"Renalytix plc","ticker":"RNLXY","form_type":"8-K","filed_at":"2024-03-13T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Renalytix raises ~$12M via two-tranche equity placing at £0.20/share","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["First tranche of 19,986,031 shares closes March 14, 2024, raising ~$5M gross.","Second tranche (26,815,841 shares) conditional on shareholder approval, raising ~$7M.","Net proceeds extend cash runway into Q4 2024 from current runway ending April 2024.","Related parties Christopher Mills and Mount Sinai subscribed for 4M and 9.36M shares respectively."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":7866336.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248369,"accession_number":"0000950170-24-024338","cik":1811115,"company_name":"Renalytix plc","ticker":"RNLXY","form_type":"8-K","filed_at":"2024-03-04T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Renalytix launches formal sale process after unsolicited approach from strategic diagnostic firm","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Unsolicited approach from a large, publicly listed diagnostics company evaluating acquisition of all shares.","Formal sale process launched; Stifel appointed as Sole Financial Adviser and Rule 3 Adviser.","Advanced financing discussions with existing shareholders and potential new equity/debt providers underway.","Cash on hand $2.3M plus $1.4M marketable securities as of March 3; expects cash to fund through April 2024.","No certainty any offer will be made; Board may pursue alternative strategic options including staying independent."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":7866336.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248368,"accession_number":"0000950170-24-022604","cik":1811115,"company_name":"Renalytix plc","ticker":"RNLXY","form_type":"8-K","filed_at":"2024-02-29T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Renalytix secures 10-year US government contract; Medicare coverage decision pending","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["KidneyIntelX.dkd added to 10-year GWAC through GSA, covering VA, DoD, IHS, at $950/result.","NGS holds Open Public Meeting on proposed coverage policy DL39726; final LCD expected FY2024.","Effective Jan 1, 2024, test priced at $950 on CMS CLFS for three years.","These advancements expected to enable insurance coverage for 10M of 14M FDA-indicated patients."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":7866336.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248367,"accession_number":"0000950170-24-015596","cik":1811115,"company_name":"Renalytix plc","ticker":"RNLXY","form_type":"8-K","filed_at":"2024-02-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Renalytix Q2 FY2024 revenue $0.7M, net loss $8.5M; CMS sets $950/test","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $0.7M from KidneyIntelX (down from $1.0M YoY); no pharma services revenue.","Net loss improved to $8.5M from $10.4M YoY; cash & equivalents $5.6M at Dec 31, 2023.","CMS finalized $950/test lab fee for kidneyintelX.dkd; NGS resumed claim payment.","Targeting ~33% lower cash burn in Q3 FY2024 vs Q2; annualized burn under $23M.","Published real-world evidence: 61% increase in kidney protective drug prescriptions after testing."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.19,"consensus_revenue_estimate":null,"consensus_revenue_actual":1168000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":7866336.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248366,"accession_number":"0000950170-24-013048","cik":1811115,"company_name":"Renalytix plc","ticker":"RNLXY","form_type":"8-K","filed_at":"2024-02-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"CMS publishes draft LCD for KidneyIntelX; coverage for type 2 diabetes and CKD stages 1-3b","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["CMS draft LCD covers KidneyIntelX and kidneyintelX.dkd for patients with type 2 diabetes and Stage 1–3b chronic kidney disease.","Medicare price set at $950 per test; distinct CPT codes on 2024 Clinical Lab Fee Schedule.","45-day public comment period opened Feb 8, 2024; ends March 23, 2024; final LCD expected in 2024.","Company formally requested the LCD from NGS and submitted peer-reviewed evidence; expert panel meeting held Aug 29, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":7866336.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248365,"accession_number":"0000950170-24-004821","cik":1811115,"company_name":"Renalytix plc","ticker":"RNLXY","form_type":"8-K","filed_at":"2024-01-17T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Renalytix announces LCD open meeting for kidneyIntelX.dkd; potential coverage for 5M more Medicare patients","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["NGS LCD Open Meeting scheduled for February 29, 2024 to discuss coverage of KidneyIntelX and kidneyintelX.dkd.","Proposed LCDs published February 8, 2024; 45-day public comment period ends March 23, 2024.","If covered, an estimated additional 5 million Medicare patients with Type 2 diabetes and early-stage CKD could gain access.","New private payer contract with Velocity National Provider Network, covering 2.7 million member lives, effective January 2024.","Final LCD expected during calendar year 2024 after public comment review."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.68,"calibrated_materiality_score":0.68,"market_cap_usd":7866336.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248364,"accession_number":"0000950170-24-003514","cik":1811115,"company_name":"Renalytix plc","ticker":"RNLXY","form_type":"8-K","filed_at":"2024-01-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Renalytix publishes real-world data showing KidneyIntelX slows CKD progression and improves diabetes control","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Study of 2,569 patients with Type 2 diabetes and DKD: KidneyIntelX deployment associated with slowed kidney function decline and improved A1C levels.","61% increase in preventative drug prescriptions among high-risk group; improved specialist referrals.","KidneyIntelX has Medicare, Medicaid, and Blue Cross coverage; FDA de novo authorization received June 2023.","27% of study cohort were Black patients; median age 68, BMI 30, 89% hypertension."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":7866336.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265862,"accession_number":"0001193125-23-305948","cik":1811115,"company_name":"Renalytix plc","ticker":"RNLXY","form_type":"8-K","filed_at":"2023-12-29T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Renalytix receives Nasdaq deficiency notices for bid price and market value","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["ADS closing bid below $1.00 for 30+ consecutive days, violating Minimum Bid Price Requirement.","Market value of listed securities below $50M threshold for continued Nasdaq Global Market listing.","Company has 180-day compliance period until June 19, 2024 to cure both deficiencies.","Failure may lead to delisting or transfer to Nasdaq Capital Market with additional cure period.","Company will monitor and may pursue options to regain compliance; no assurance of success."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":7866336.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265861,"accession_number":"0000950170-23-071065","cik":1811115,"company_name":"Renalytix plc","ticker":"RNLXY","form_type":"8-K","filed_at":"2023-12-18T23:59:59+00:00","items":["3.02","7.01","9.01"],"status":"ready","headline":"Renalytix repays $1.06M of convertible bond via 2.5M shares and $600k cash; remaining principal $13.78M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Repayment of $1.06M principal and interest due Jan 7, 2024 using 2.5M ordinary shares and $600k cash.","After settlement, remaining convertible bond principal reduced to $13.78M from $14.84M.","2.5M new ordinary shares admitted to AIM on December 21, 2023; total voting rights become 99,930,156.","Shares issued under Section 3(a)(9) exemption; no registration required."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":7866336.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265860,"accession_number":"0000950170-23-070946","cik":1811115,"company_name":"Renalytix plc","ticker":"RNLXY","form_type":"8-K","filed_at":"2023-12-18T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Renalytix annual meeting Dec 15: all proposals pass; ~41% of shares voted","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All 10 proposals passed at AGM on Dec 15, including adoption of FY2023 accounts, director re-appointments, and auditor ratifications.","Approximately 41.27% of shares (40.2 million ordinary shares) were represented at the meeting.","Directors authorized to allot shares up to aggregate nominal value of £85,251.39 and sell treasury shares.","Market purchase authority granted for buybacks on London Stock Exchange.","New articles of association adopted."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":7866336.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265859,"accession_number":"0000950170-23-069033","cik":1811115,"company_name":"Renalytix plc","ticker":"RNLXY","form_type":"8-K","filed_at":"2023-12-08T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Director Chirag Parikh resigns from Renalytix board effective Dec 5, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Chirag Parikh resigned from the Board effective December 5, 2023.","Resignation was not due to any disagreement with the Company or Board.","Resolution to re-appoint Dr. Parikh at the December 15, 2023 AGM (resolution 4) is withdrawn.","Withdrawal does not affect other AGM resolutions or proxy votes already submitted.","Dr. Parikh will not stand for re-appointment at the AGM."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":7866336.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265858,"accession_number":"0000950170-23-063352","cik":1811115,"company_name":"Renalytix plc","ticker":"RNLXY","form_type":"8-K","filed_at":"2023-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Renalytix Q1 FY2024 revenue drops 50% YoY to $0.5M; net loss $10.2M; cost cuts underway","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $0.5M, down 50% from $1.0M in Q1 FY2023; net loss $10.2M vs $12.0M.","Cost cutting to reduce payroll >35% and total SG&A >30% YoY; cash $13.9M.","Testing volumes 1,297 (56% billable); CMS recommended $950/test for kidneyintelX.dkd, decision Dec 2023.","Howard Doran appointed chief business officer; financing discussions for runway through early 2026.","Expanded commercial payor coverage: BlueCross BlueShield Texas (7M members), Parkland, PNOA."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":459000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":7866336.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265857,"accession_number":"0000950170-23-056841","cik":1811115,"company_name":"Renalytix plc","ticker":"RNLXY","form_type":"8-K","filed_at":"2023-10-31T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Renalytix sets AGM for Dec 15, 2023; publishes Annual Report for FY2023","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["AGM to be held in-person on December 15, 2023 at 15:30 GMT at 6 Stratton Street, London.","Annual Report for year ended June 30, 2023 published on company website.","Shareholders without e-consent will receive printed Annual Report by post.","Attendance registration required via Walbrook PR; contact details provided.","No financial results or guidance changes announced in this filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":7866336.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265856,"accession_number":"0000950170-23-054705","cik":1811115,"company_name":"Renalytix plc","ticker":"RNLXY","form_type":"8-K","filed_at":"2023-10-24T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Director Timothy J. Scannell resigns from Renalytix board effective immediately","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Timothy J. Scannell resigned from the Board on October 18, 2023, effective immediately.","Resignation was not due to any disagreement with the Company or the Board.","No replacement named at this time."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":7866336.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265855,"accession_number":"0000950170-23-053654","cik":1811115,"company_name":"Renalytix plc","ticker":"RNLXY","form_type":"8-K","filed_at":"2023-10-17T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Renalytix repays $1.06M of convertible bond with equity, principal now $14.84M","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Repaid $1.06 million of convertible bond via 150,000 ordinary shares and 1,092,694 ADSs.","Remaining convertible bond principal reduced to $14.84 million.","Total shares outstanding after admission: 97,430,156 ordinary shares.","New ordinary shares expected to be admitted to AIM on October 19, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":7866336.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265854,"accession_number":"0000950170-23-051276","cik":1811115,"company_name":"Renalytix plc","ticker":"RNLXY","form_type":"8-K","filed_at":"2023-10-03T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"CMS sets Medicare price for Renalytix's kidneyintelX.dkd test at $950, effective Jan 2024","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["CMS published price for FDA-authorized kidneyintelX.dkd test on national Clinical Lab Fee Schedule at $950.","Pricing effective Jan 1, 2024 and maintained for a minimum of three years.","AMA panel recommended a new CPT code to differentiate kidneyintelX.dkd from the original LDT, triggering the pricing review.","Company states the CMS action affirms KidneyIntelX platform value and aids in expanding insurance coverage."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":7866336.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":283073,"accession_number":"0000950170-23-050236","cik":1811115,"company_name":"Renalytix plc","ticker":"RNLXY","form_type":"8-K","filed_at":"2023-09-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Renalytix reports FY2023 results: FDA authorization, 55% test growth, $11M cost cuts","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["FDA De Novo marketing authorization for KidneyIntelX.dkd to assess kidney decline risk in diabetic patients.","Over 5,000 KidneyIntelX tests performed in FY2023, up 55% from prior year.","Reduced annual operating expenses by over $11M vs prior year; additional cuts underway.","Completed $20.3M equity financing in February 2023 led by new institutional investors.","Secured multiple insurance contracts including EmblemHealth and CareFirst; over 40 commercial payors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":7866336.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":283072,"accession_number":"0000950170-23-049314","cik":1811115,"company_name":"Renalytix plc","ticker":"RNLXY","form_type":"8-K","filed_at":"2023-09-22T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Renalytix expands KidneyIntelX insurance coverage with BCBSTX and Parkland Community Health Plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["BlueCross BlueShield of Texas (7M members) contract adds largest statewide health plan coverage for KidneyIntelX.","Parkland Community Health Plan (Dallas, 300k+ covered lives) also agrees to cover KidneyIntelX.","Supplemental to existing coverage with Wellmark (2.1M), BCBS Illinois (8.1M), and CareFirst (3.4M).","KidneyIntelX targets prognostic testing for type 2 diabetes and early-stage kidney disease in large populations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":7866336.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":283071,"accession_number":"0000950170-23-047260","cik":1811115,"company_name":"Renalytix plc","ticker":"RNLXY","form_type":"8-K","filed_at":"2023-09-08T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Renalytix appoints Howard Doran as Chief Business Officer to lead KidneyIntelX sales","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Howard Doran appointed Chief Business Officer effective Sept 1, 2023, to lead KidneyIntelX global sales.","Doran brings 30+ yrs diagnostics exp; served as CEO of LipoScience (acquired by LabCorp) and President of Hologic Global Diagnostics.","Annual base salary of $300,000; target bonus 60% of base; options for 300,000 ordinary shares with 3-yr vesting and 1-yr cliff.","Renalytix commercializes FDA-approved AI prognostic blood test for type 2 diabetes and chronic kidney disease."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":7866336.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":283070,"accession_number":"0000950170-23-043554","cik":1811115,"company_name":"Renalytix plc","ticker":"RNLXY","form_type":"8-K","filed_at":"2023-08-21T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Renalytix's KidneyIntelX included in draft KDIGO 2023 chronic kidney disease guidelines","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Public comment period on draft KDIGO 2023 guidelines closed; final version expected Q4 2023.","KDIGO is a global nonprofit; guidelines are followed by clinicians worldwide.","Inclusion, if finalized, could drive broader adoption and reimbursement for KidneyIntelX in US and abroad.","Renalytix notes inclusion in draft does not guarantee inclusion in final guidelines."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":7866336.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":283069,"accession_number":"0000950170-23-033233","cik":1811115,"company_name":"Renalytix plc","ticker":"RNLXY","form_type":"8-K","filed_at":"2023-07-17T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Renalytix repays $1.06M of convertible bond via ADS issuance; principal reduced to $15.9M","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Repaid $1.06M of convertible bond by issuing 526,211 American Depositary Shares (1,052,422 ordinary shares).","Remaining principal under the convertible bond after settlement is $15.90M.","New ordinary shares admitted to trading on AIM effective July 19, 2023.","Post-admission total ordinary shares outstanding: 94,833,900.","Announcement corrects prior figure for principal remaining from earlier release."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":7866336.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":283068,"accession_number":"0000950170-23-031366","cik":1811115,"company_name":"Renalytix plc","ticker":"RNLXY","form_type":"8-K","filed_at":"2023-07-03T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Renalytix appoints Catherine Coste to Board of Directors as Audit Chair","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Catherine Coste, former Deloitte senior partner, appointed to board effective June 30, 2023.","She will serve as Non-Executive Chair of Audit Committee and member of Remuneration Committee.","Compensation: $40k/year director fee, plus $20k for Audit Chair, $7k for Remuneration Committee.","Coste has 32 years finance experience, CPA, and serves on two other public company boards."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":7866336.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":283067,"accession_number":"0000950170-23-031264","cik":1811115,"company_name":"Renalytix plc","ticker":"RNLXY","form_type":"8-K","filed_at":"2023-07-03T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Renalytix transitions to U.S. domestic issuer status, adopts new disclosure channels","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Effective July 1, 2023, Renalytix began filing periodic reports and registration statements on U.S. domestic issuer forms.","Previously qualified as a foreign private issuer; now required to file more detailed and timely disclosures with the SEC.","Company will disseminate material information via SEC filings, press releases, public calls, its website, and LinkedIn.","Investors encouraged to monitor listed channels for potentially material information."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":7866336.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}